Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

143 results about "Control animal" patented technology

Administration of plant expressed oral tolerance agents

Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine hemophilia B as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of coagulation factor IX (F. IX) expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated mice when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after 4 to 6 exposures to intravenous F. IX protein. While only 20-25% of control animals survived after 6-8 F. IX doses, 90-95% of tolerized mice survived 12 injections without signs of allergy or anaphylaxis. This high-responder strain of hemophilia B mice represents the first hemophilic animal model to study anaphylactic reactions. The plant material was effective over a range of oral antigen doses (equivalent to 5-80 μg recombinant F.IX/kg), and controlled inhibitor formation and anaphylaxis long-term, up to 7 months. Oral antigen administration caused a deviant immune response that suppressed formation of IgE and inhibitory antibodies. This cost-effective and efficient approach to oral delivery of protein antigens to the gut should be applicable to several genetic diseases that are prone to pathogenic antibody responses during treatment.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Method for controlling animal robot to turn on basis of ventral posterior medial nucleus electrical stimulation

InactiveCN104679028AControllable steering angleOmit training timeControl using feedbackControl animalThalamus
The invention relates to a method for controlling an animal robot to turn on the basis of ventral posterior medial nucleus electrical stimulation. The method comprises the steps that two stimulating electrodes are respectively imbedded into VPM (Ventral Posterior Medial Nucleus) regions on both sides of the animal robot, the electrodes are fixed on skulls with dental cement, and an electrical stimulation backpack is installed on the animal robot; waveform parameters of electrical stimulation are set by an upper computer and are transmitted to the electrical stimulation backpack at the back of the animal robot in a wireless mode, the stimulating electrodes are controlled by the electrical stimulation backpack, so as to perform electrical stimulation on the animal robot, and corresponding thalamus-cortex projection loops are activated, so that the animal robot generates a virtual feeling, so as to complete turning. According to the method, a traditional method that the animal robot learns to turn by reward training is eliminated, turning is realized directly through the electrical stimulation, the controllability over a turning angle is realized, a large amount of training time is saved, the working efficiency is high, and the method has good application prospects in the field of animal robot navigation.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products